RT Journal Article SR Electronic T1 Gemcitabine Re-challenge in Metastatic Soft Tissue Sarcomas: A Therapeutic Option for Selected Patients JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 347 OP 351 DO 10.21873/anticanres.13118 VO 39 IS 1 A1 ANA SEBIO A1 ANASTASIA CONSTANTINIDOU A1 CHARLOTTE BENSON A1 GEORGIOS ANTONIOU A1 CHRISTINA MESSIOU A1 AISHA MIAH A1 SHANE ZAIDI A1 ANN PETRUCKEVITCH A1 OMAR AL-MUDERIS A1 KHIN THWAY A1 WINETTE T. VAN DER GRAAF A1 ROBIN L. JONES YR 2019 UL http://ar.iiarjournals.org/content/39/1/347.abstract AB Background/Aim: Treatment options for patients with metastatic soft tissue sarcomas are limited. Re-challenge with a previously successful gemcitabine-based regimen is common. There are no published data to support this practice. Patients and Methods: We conducted a retrospective search to identify patients re-challenged with gemcitabine-based chemotherapy (GBC) from 2003 to 2015. Results: Twenty-nine patients re-challenged with gemcitabine were identified. The response rate for initial GBC was 55% (n=15) and for re-challenge GBC 26% (n=6). The median progression-free survival was 11.1 months (95%CI=7.2-11.9) for initial GBC and 5.3 months (95%CI=2.0-7.5) for re-challenge GBC. Overall survival following gemcitabine re-challenge was 12.2 months (95%CI=7.0-18.2). Twelve out of 26 evaluable patients (46%) treated with re-challenge GBC experienced grade 3-4 adverse events (CTCAE 4.03) with 31% (n=8) of patients requiring dose reduction. Conclusion: In selected patients, gemcitabine re-challenge can be considered in advanced sarcomas, however, this approach is associated with toxicity.